Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 18, 2009, Pages 7537-7541

  Zhang, Pei ^a   Zhong, Lilin ^a   Struble, Evi Budo ^a   Watanabe, Hisayoshi ^b   Kachko, Alla ^b   Mihalik, Kathleen ^b   Virata Theimer, Maria Luisa ^a   Alter, Harvey J ^a,c   Feinstone, Stephen ^b   Major, Marian ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBODY; EPITOPE; GLYCOPROTEIN E1; GLYCOPROTEIN E2; IMMUNOGLOBULIN; PEPTIDE; GLYCOPROTEIN E2, HEPATITIS C VIRUS; HEPATITIS C ANTIBODY; HEPATITIS VACCINE; VIRUS ENVELOPE PROTEIN;

ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CHIMPANZEE; CHRONIC PATIENT; CONTROLLED STUDY; DEPLETION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; PLASMA; PRIORITY JOURNAL; VACCINATION; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; ANIMAL; BLOOD; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; PAN TROGLODYTES; SERODIAGNOSIS;

HEPATITIS C VIRUS; PAN;

AMINO ACID SEQUENCE; ANIMALS; EPITOPES; GENOTYPE; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PAN TROGLODYTES; VACCINATION; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

EID: 66149135701     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0902749106     Document Type: Article

References (22)

1. Alter HJ, Seeff LB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20:17-35.
2. Davis GL (2006) Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl 12:1317-1319.
3. Yu MW, et al. (2004) Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci USA 101:7705-7710.
4. Zhang P, et al. (2007) Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 104:8449-8454.
5. Triyatni M, etal. (2002) Structural featuresof envelope proteinson hepatitis Cvirus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 298:124-132.
6. Hsu M, et al. (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entryof pseudotyped retroviral particles. Proc Natl Acad Sci USA 100:7271-7276.
7. Tarr AW, et al. (2007) Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol 88:2991-3001.
8. Perotti M, et al. (2008) Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 82:1047-1052.
9. Law M, et al. (2008) Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 14:25-27.
10. Logvinoff C, et al. (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 101:10149 -10154.
11. Kato T, et al. (2003) Efficient replication of the genotype 2a hepatitis C virus sub- genomic replicon. Gastroenterology 125:1808-1817.
12. Lindenbach BD, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
13. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497.
14. Puig M, Major ME, Mihalik K, Feinstone SM (2004) Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22:991-1000.
15. Tarr AW, et al. (2006) Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology43:592-601.
16. Flint M, et al. (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73:6235-6244.
17. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH (2001) Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82:1877-1883.
18. Clayton RF, et al. (2002) Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 76:7672-7682.
19. Owsianka AM, et al. (2006) Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. JVirol 80:8695-8704.
20. Li Y, et al. (2007) Broad HIV-1 neutralization mediated byCD4-binding site antibodies. Nat Med 9:1032-1034.
21. Zhang P, Yu MW, Venable R, Alter HJ, Shih JW (2006) Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees. Proc Natl Acad Sci USA 103:9214-9219.
22. Barany G, Merrifield RB (1980) Solid-phase peptide syntheses. The peptides: analysis, synthesis and biology, ed Gross E, Meienhofer J (Academic, New York, NY), pp 1-284.